Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin versus lopinavir/ritonavir for COVID-19
ChiCTR2000029867Phase 4Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Feb 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carrimycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoints: Body temperature returns to normal time, Pulmonary inflammation resolution time (HRCT) and 1 more. Started Feb 2020; status: recruiting.
02
Drugs
carrimycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029867.